Deep 6 AI vs Massive Bio (2026)
Two trial matching companies that reach the patient from opposite directions. Deep 6 deploys inside the institution, reading unstructured notes, pathology, genomics and laboratory data to match patients and sites in real time across therapeutic areas, and covering feasibility as well as enrolment. Massive Bio needs no integration at all, matching oncology and haematology patients against a very large trial list with certified case managers auditing every match, and it reaches patients directly as well as through sites. For a health system building trial capacity into routine care, Deep 6 is the infrastructure. For a patient whose oncologist runs no trials, Massive Bio is the only one of the two that will ever find them, which is a real difference in who gets access.
- It reads unstructured clinical data across notes, pathology, genomics and laboratory reports to match patients and sites in real time across therapeutic areas.
- Coverage spans feasibility and cohort building at study design through enrolment, so sponsors and sites use the same platform.
- It deploys inside the institution rather than requiring patients to find it, which suits a health system building trial capacity.
- It matches without requiring an integration at all, which removes the longest pole in most trial matching deployments.
- Every generated match is audited by certified oncology case managers before it is used, so a human sits structurally in the path.
- It reaches patients directly as well as through sites, so a patient whose oncologist has no trial programme is not excluded by their institution.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Deep 6 AI and Massive Bio are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Deep 6 AI | Massive Bio |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2016 | 2015 |
| Headquarters | Pasadena, California, United States | Boca Raton, Florida |
| Website | deep6.ai | massivebio.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Deep 6 AI its top capability grade on AI Centrality. Set against Massive Bio, Deep 6 AI does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Security Certifications and Trust Center and AI Governance and Bias Disclosure. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Massive Bio its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Deep 6 AI, Massive Bio grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Deep 6 AI or Massive Bio?
The AI Health Index grades Massive Bio higher than Deep 6 AI on every axis that separates them, several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Deep 6 AI does not grade higher on any scored axis.
Where do Deep 6 AI and Massive Bio differ most?
The widest separation the AI Health Index records between Deep 6 AI and Massive Bio is on Model Supply Chain Disclosure, where Deep 6 AI grades D and Massive Bio grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Deep 6 AI and Massive Bio grade the same?
The AI Health Index grades Deep 6 AI and Massive Bio the same on several axes, including AI Centrality, Security Certifications and Trust Center and AI Governance and Bias Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Deep 6 AI and Massive Bio not disclosed?
At the last review, at least one of Deep 6 AI and Massive Bio published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Both carry the documentation bias that defines trial matching: a patient with a thin or fragmented record matches less often regardless of eligibility, and that population overlaps with the one trials already under enrol. Neither publishes the false negative rate on eligibility screening, which is the only real measure of a matching system. Deep 6 publishes no attestation scoped to the platform, no business associate terms and no governance framework. Massive Bio's patient facing route raises a separate question about who pays for a match a patient found themselves.